Education
About Us
Working with TipRanks
Follow Us
Compugen (CGEN)
:CGEN
CGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.13 - $2.66
Previous CloseN/A
Volume276.40K
Average Volume (3M)238.98K
Market Cap
$136.56M
Enterprise Value$75.57M
Total Cash (Recent Filing)$57.51M
Total Debt (Recent Filing)$1.41M
Price to Earnings (P/E)87.5
Beta1.70
Next Earnings
Nov 06, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding93,535,355
10 Day Avg. Volume186,295
30 Day Avg. Volume238,980
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue10.08
Enterprise Value/Gross Profit11.58
Enterprise Value/Ebitda-2.22
Forecast
1Y Price Target
$7.00Price Target Upside389.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCompugen ended the quarter with $104M cash and equivalents, which is expected to fund operations into 2027.
Partnerships And CollaborationsCompugen’s partner AZN’s continued expansion of rilvegostomig meaningfully derisks the royalty stream to Compugen, minimizing capital risk and setting a baseline valuation for CGEN.
Stock Rating And Price TargetThe price target has been revised to $10 from $7, reiterating an outperform (OP) rating.
Bears Say
Investor SentimentInvestor sentiment on the TIGIT class remains severely negative given multiple trial failures and discontinuations of Fc-competent TIGIT antagonists.
Market DependenciesSignificant CGEN upside or downside is tied to Arcus and Gilead’s earlier Ph 3 trials of their Fc-silent TIGIT in gastric and lung cancers.
Trial And Research OutcomesInvestors are expected to put little value in post-hoc analysis of which patients benefit most from COM701.
Compugen News
CGEN FAQ
What was Compugen’s price range in the past 12 months?
Compugen lowest stock price was $1.13 and its highest was $2.66 in the past 12 months.
What is Compugen’s market cap?
Compugen’s market cap is $136.56M.
When is Compugen’s upcoming earnings report date?
Compugen’s upcoming earnings report date is Nov 06, 2025 which is in 75 days.
How were Compugen’s earnings last quarter?
Compugen released its earnings results on Aug 06, 2025. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.062 by -$0.018.
Is Compugen overvalued?
According to Wall Street analysts Compugen’s price is currently Undervalued.
Does Compugen pay dividends?
Compugen does not currently pay dividends.
What is Compugen’s EPS estimate?
Compugen’s EPS estimate is -0.07.
How many shares outstanding does Compugen have?
Compugen has 93,535,355 shares outstanding.
What happened to Compugen’s price movement after its last earnings report?
Compugen reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.062. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Compugen?
Currently, no hedge funds are holding shares in CGEN
Compugen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (389.51% Upside)
$7.00 (389.51% Upside)
Blogger Sentiment
Bullish
CGEN Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 183.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.92%
12-Months-Change
Fundamentals
Return on Equity
-35.66%
Trailing 12-Months
Asset Growth
-3.31%
Trailing 12-Months
Company Description
Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
CGEN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mix of strong leadership transitions, financial stability, and strategic advancements in the clinical pipeline, particularly with COM701 and the TIGIT program. However, these positives are tempered by decreased revenues, increased net losses, and competitive challenges in the market.View all CGEN earnings summariesCGEN Stock 12 Month Forecast
Average Price Target
$7.00
▲(389.51% Upside)
Technical Analysis
Ownership Overview
―
Insiders
2.68% Mutual Funds
8.48% Other Institutional Investors
88.16% Public Companies and
Individual Investors